GlassScriptPhysician profile
Syed H Abid
NPI 1013902006
$17,170.74
in general payments reported to CMS, 2019-2025
81 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $1,613 · 2021: $1,688 · 2022: $2,509 · 2023: $3,277 · 2024: $3,140 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,690 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,689.77 |
| Education | $131.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,958.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,396.27 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $1,243.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,164.42 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Daiichi Sankyo INC. | $768.11 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $617.01 | 2019-2024 | Enhertu, Imfinzi, Lynparza |
| Seagen INC. | $606.49 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Celgene Corporation | $538.43 | 2020-2025 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $528.71 | 2019-2025 | Xtandi, Padcev |
| Glaxosmithkline, LLC. | $509.63 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Janssen Biotech, INC. | $503.35 | 2019-2025 | Erleada, Balversa, Akeega |
| Incyte Corporation | $482.57 | 2019-2025 | Jakafi |
| Exelixis INC. | $436.49 | 2019-2024 | Cabometyx |
| Amgen INC. | $418.79 | 2019-2024 | Evenity, Prolia, Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $408.54 | 2021-2025 | Fruzaqla, Alunbrig, Ninlaro |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.55 | 2019-2025 | Lupron Depot |
| Regeneron Healthcare Solutions, INC. | $370.41 | 2022-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $318.61 | 2020-2025 | |
| Gilead Sciences, INC. | $301.52 | 2021-2025 | Trodelvy |
| Kite Pharma, INC. | $264.13 | 2020-2025 | Yescarta |
| Array Biopharma INC | $256.69 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $251.88 | 2020-2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $250.88 | 2019-2025 | Phesgo, Kadcyla, Perjeta |
| Lilly USA, LLC | $233.06 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.00 | 2019-2025 | Gilotrif |
| Stemline Therapeutics INC. | $153.01 | 2023-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $144.04 | 2020-2024 | Xpovio |
| Puma Biotechnology, INC. | $134.64 | 2020-2025 | |
| Tempus Ai, INC | $131.69 | 2024-2025 | Xt Cdx |
| Tersera Therapeutics LLC | $124.59 | 2019-2024 | Zoladex |
| Mirati Therapeutics, INC. | $112.59 | 2023-2024 | Krazati |
| Celltrion USA INC. | $111.65 | 2023 | Vegzelma |
| Eisai INC. | $99.20 | 2019-2023 | |
| Fennec Pharmaceuticals, INC. | $98.68 | 2024 | Pedmark |
| Pharmacyclics LLC, An Abbvie Company | $84.23 | 2021-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $83.73 | 2019-2024 | Somatuline Depot, Onivyde |
| Aveo Pharmaceuticals, INC. | $74.84 | 2022-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $63.51 | 2021-2022 | |
| Taiho Oncology, INC. | $56.33 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $56.18 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Acrotech Biopharma INC. | $52.78 | 2021-2022 | |
| Beone Medicines USA, INC. | $51.10 | 2025 | Tevimbra |
| Caris Mpi, INC. | $51.09 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $49.56 | 2023-2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $46.20 | 2023-2024 | |
| Amag Pharmaceuticals, INC. | $43.45 | 2019 | |
| Verity Pharmaceuticals INC. | $42.23 | 2022-2025 | Trelstar |
| Legend Biotech USA INC. | $41.32 | 2025 | Carvykti |
| Cti Biopharma Corp. | $39.17 | 2022-2023 | Vonjo |
| Sobi, INC | $39.09 | 2025 | |
| Agios Pharmaceuticals, INC. | $36.99 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $35.83 | 2019-2021 | |
| Partner Therapeutics, INC. | $34.87 | 2019 | |
| Foundation Medicine, INC. | $34.57 | 2021 | |
| Sumitomo Pharma America, INC. | $34.35 | 2023 | Orgovyx |
| Pharmaessentia USA Corporation | $34.03 | 2025 | Besremi |
| Dova Pharmaceuticals | $32.07 | 2020-2021 | |
| Immunocore Limited | $31.73 | 2025 | Kimmtrak |
| Novo Nordisk INC | $29.72 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.88 | 2019-2022 | |
| Geron Corporation | $26.44 | 2025 | Rytelo |
| Heron Therapeutics, INC. | $26.02 | 2022 | |
| Ge Healthcare | $25.97 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.64 | 2025 | Romvimza, Qinlock |
| Recordati_rare_diseases_inc. | $22.73 | 2023 | Sylvant |
| Epizyme, INC. | $21.21 | 2021 | |
| Morphosys, US INC. | $20.64 | 2023 | Monjuvi |
| Octapharma USA, INC. | $20.08 | 2020 | |
| Servier Pharmaceuticals LLC | $19.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.17 | 2020 | |
| Fresenius Kabi USA, LLC | $18.91 | 2024 | Stimufend |
| Blueprint Medicines Corporation | $18.79 | 2023 | Ayvakit |
| Myovant Sciences INC. | $18.41 | 2022 | |
| Global Blood Therapeutics, INC. | $18.23 | 2022 | |
| Emmaus Medical, INC. | $16.72 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.91 | 2023 | Avastin |
| Kyowa Kirin, INC. | $15.84 | 2021 | |
| Inari Medical, INC. | $15.48 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $15.08 | 2021 | |
| Organon LLC | $14.83 | 2022 | |
| Emd Serono, INC. | $14.23 | 2022 |
Drugs and devices associated with these payments
Keytruda $728Opdivo $569Enhertu $506Reblozyl $455Jakafi $331Kisqali $316Ibrance $306Lynparza $291Adcetris $286Tukysa $275Xtandi $272Libtayo $272Elrexfio $269Braftovi $222Inlyta $212Jemperli $207Imbruvica $200Mektovi $198Erleada $195Lorbrena $194Ojjaara $192Fruzaqla $187Krazati $187Epkinly $180Talzenna $172Padcev $167Orserdu $153Venclexta $144Xt Cdx $132Fabhalta $119Vegzelma $112Bosulif $111Zejula $106Yescarta $105Opdualag $103Scemblix $102Brukinsa $99.54Pedmark $98.68Gilotrif $98.58Comirnaty $95.28Sarclisa $94.32Balversa $93.92Cablivi $92.41Enjaymo $92.41Lutathera $87.72Tevimbra $85.08Pluvicto $82.46Piqray $82.07Injectafer $79.66Lupron Depot $76.78Imfinzi $75.91Paxlovid $74.19Xpovio $73.40Trodelvy $73.19Promacta $71.75Lenvima $71.18Phesgo $67.54Kadcyla $67.54Perjeta $67.54Akeega $62.00Keytruda Qlex $60.83Blenrep $59.61Alunbrig $59.48Vonjo $58.72Fotivda $56.38Lonsurf $56.33Inqovi $56.33Tavalisse $56.18Rezlidhia $56.18Welireg $52.59Cabometyx $51.23Mi Cancer Seek $51.09Augtyro $47.35Nubeqa $46.20Xofigo $46.20Jaypirca $45.02Verzenio $45.02Datroway $44.39Carvykti $41.32Polivy $40.72Bavencio $39.17Mekinist $38.94Besponsa $36.76Orgovyx $34.35Besremi $34.03Kimmtrak $31.73Lynozyfic $29.67Oxbryta $29.26Zoladex $27.93Trelstar $27.84Evenity $27.59Prolia $27.59Rytelo $26.44Gavreto $26.27Ninlaro $25.72Qinlock $24.64Romvimza $24.64Lunsumio $23.84Gazyva $23.84Retevmo $22.97
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Abid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.